"The voice for cancer physicians and their patients in Massachusetts."

FDA Approves Dasatinib (Sprycel) for the Pediatric Patients with PH+ CML in chronic Phase

16 Nov 2017 10:53 AM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration granted regular approval to dasatinib (Sprycel; Bristol-Myers Squibb) for the treatment of pediatric patients with Philadelphia chromosome-positive (PH+) chronic myeloid leukemia (CML) in the chronic phase. Read full press release.

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software